SECTOR:
Other therapeutics
FUND/VEHICLE:
NFLS Direct Investment
INVESTMENT DATE:
2015
GEOGRAPHY:
North America
STATUS CURRENT/FORMER INVESTMENT:
Existing
WEBSITE:
CHROMADERM is developing a
first-in-class treatment for melasma and
other skin hyperpigmentation disorders.
The team will in-license and re-purpose
Ruboxistaurin, a potent and selective
protein kinase C-beta (“PKCβ”) inhibitor
from Eli Lilly. Unlike the existing
skin-lightening agents, Ruboxistaurin
presents a potentially safer and more
efficacious approach.